Rumensin 20% Millmix

Rumensin™ (Monensin as monensin sodium)

The essential ingredient!
Rumensin Max

Rumensin™ (Monensin as monensin sodium)

The essential ingredient!
Rumensin Select

Rumensin™ (Monensin as monensin sodium)

The essential ingredient!
Rumensin Capsule

Rumensin™ (Monensin as monensin sodium)

100-day peace of mind
Cattle Tylan 200 Injection

Tylan™ 200 Injection (Tylosin injection)

Knock out Mastitis

Imrestor™ (Pegbovigrastim injection)

Protect her Potential

Keto-Test™ for testing milk ketones (Beta-hydroxybutyric acid)


Fasinex™ 24

Oral flukicide for cattle
Fasimec Pour On

Fasimec™ Cattle Pour-On

Flukicide and broad spectrum anthelmintic.

Tylan™ 200 Injection (Tylosin injection)
Tylan™ 200 Injection (Tylosin injection)

Knock out Mastitis

This is a restricted veterinary medicine. This product is available only under veterinary authorisation. Managing immune function, restoring energy balance and providing effective therapy for periparturient diseases during The Vital 90 Days™ – i.e. the critical period from two months before calving to one month after calving – helps to protect the cow’s lactation potential by minimising transition disorders and maximising productivity.

Tylan™ 200 Injection is the first choice for the parenteral therapy of periparturient diseases. It contains 200 mg/mL of the active ingredient, tylosin, which has extremely low Minimum Inhibitory Concentrations (MIC) against most pathogens associated with mastitis, metritis, pneumonia and foot rot.1 Tylosin has an antibacterial spectrum that is essentially gram-positive. It is also active against certain gram-negative organisms and mycoplasma species.

Early detection and treatment with an effective antibiotic during the early stages of infection will minimise long-term tissue damage, allowing the quarter to return to normal milk production in subsequent lactations. Tylan™ 200 Injection is highly effective against the key pathogens associated with mastitis, including Staphylococcus aureus and Streptococcus uberis1, making it an excellent choice for those situations when there is a mixed pathogen spectrum or the causative agent is unknown.

Tylan™ 200 Injection is ideal for use in those cases where cows do not respond to IMM therapy or where it may be compromised by swelling of the mammary gland. Alternatively, Tylan™ 200 Injection can provide augmented treatment in combination with IMM therapies, particularly against mixed infections.

First choice for controlling metritis

Tylan™ 200 Injection is effective against pathogens that attack the reproductive tract and cause metritis, including Trueperella pyogenes (previously known as Actinomyces pyogenes), Staphylococcus aureus, Streptococcus spp, Fusobacterium necrophorum and Clostridium spp.1,2 One study showed Tylan™ 200 Injection is still fighting bacteria at the site of infection while being virtually undetectable in the blood, even 30 hours after injection.3

First choice for controlling respiratory disease

Tylan™ 200 Injection moves rapidly to the lungs, where it begins to accumulate within 30 minutes of injection. It controls a range of pathogens associated with respiratory disease, including Acholeplasma laidlawii, Clostridium perfringens, Fusobacterium necrophorum, Haemophilus somnus, Mycoplasma bovirhinus, Mycoplasma bovis, Mycoplasma dispar, Pasteurella haemolytica and Pasteurella multocida.1,2

First choice for controlling footrot

Tylan™ 200 Injection is effective against a variety of bacteria, including Trueperella pyogenes (previously known as Actinomyces pyogenes) and Fusobacterium necrophorum, associated with foot rot.1,2

Important Safety Information

Always read, understand, and follow label directions.

Withholding Periods

Milk collected from cows within 72 hours (i.e. six milkings) following treatment must not be used for human consumption or processing, or fed to bobby calves.

Do not use in cattle less than 21 days before slaughter for human consumption.

Any variation by the prescribing veterinarian to the approved dose, frequency, duration, route, disease, or target species may require extending the approved withholding period.

Directions For Use


Success has been reported in the use of Tylan™ 200 Injection for the control of the following disease conditions:

Cattle: Respiratory infections, Foot-rot (necrotic pododermatitis), Calf diphtheria, Metritis, Acute mastitis.

Sheep and Goats: The treatment of the early stages of the peracute and acute forms of contagious agalactia caused by Mycoplasma agalactiae and caprine pleuropneumonia caused by Mycoplasma mycoides var. Capri (M. Capri).

Pigs: Swine dysentery and enteritis associated with the presence of Lawsonia intracellularis and other organisms sensitive to tylosin, Swine Erysipelas, Pneumonia and Arthritis due to Mycoplasma.

Dosage and administration

Inject 5–10 mg tylosin per kilogram of bodyweight daily intramuscularly or by slow intravenous injection (equivalent to 0.5–1 mL Tylan™ 200 tylosin injection per 20 kg bodyweight). Treatment should be continued 24 hours following remission of disease signs. If there is no response to therapy in three days, diagnosis and treatment should be reassessed. Do not exceed five days of treatment.

Efficacy spectrum

Tylan™ possesses a wide spectrum of antibiotic activity and is active against gram positive bacteria, including Staphylococci, Streptococci, Corynebacteria spp. and Erysipelothrix rhusiopathiae (insidiosa). It is also active against certain gram negative bacteria, e.g. Lawsonia intracellularis and certain spirochaetes. It has been found to be extremely active against Mycoplasma species isolated from both avian and mammalian hosts, including cattle, sheep, goats and pigs.


There are no known contra-indications to Tylan™ 200 Injection. Do not mix Tylan™ 200 Injection with other parenteral solutions as this may cause precipitation of the active ingredient.


1 Pridmore, Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) of tylosin and erythromycin against aerobic bacterial pathogens of cattle and swine, 2004, Elanco Study No T1YUK0303.

2 Chamberland, S. (1993). Intracellular accumulation of tylosin in primary swine and bovine alveolar macrophages, Elanco Data on File.

3 Cester, et al. (1993). Research in Veterinary Science 54:32.

Registered pursuant to the ACVM Act 1997, No. A907.
See for registration conditions